QResearch data reveals risks of clinical outcomes for diabetes drugs with help from EMIS Health

31 Mar 2016

Important research published in The BMJ this week has found clinically important differences between different diabetes drugs for risk of key outcomes.

The research, using information from the QResearch database - a joint not-for-profit project from the University of Nottingham and EMIS Health – compared diabetes drugs, particularly newer drugs (thiazolidinediones and gliptins) in their ability to control blood sugar levels and prevent serious complications.

Professors Julia Hippisley-Cox and Carol Coupland at the University of Nottingham used the QResearch database of anonymised patient records to analyse records of 469,688 adult patients with Type 2 diabetes from 2007-2015.

They found clinically important differences between different drugs (alone and in combination) and risk of five key outcomes – blindness, amputation, severe kidney failure, high blood sugar and low blood sugar.

Read the story in full on the EMIS Health website.

Read the full research paper